Mathematical Modeling of Strategic Treatments on Tumor Growth

Jyotsna Baloni; U. S. Rana

Authors

Jyotsna Baloni
U. S. Rana

mathematical modeling, chemotherapy, effector cell, il-2, adoptive immunotherapy

Abstract

We propose to contribute to the emerging body of cancer treatment research by developing and analyzing mathematical models of the treatment of tumor with various strategic treatments. We build on existing models of the immunology that are already successfully developed and then the effects of chemotherapy and interleukin-2 were applied to the model. Thus we build a mathematical model of tumour and effector cell with scheduled chemotherapy.The effect of scheduled il2 dose with chemotherapy and adoptive immunotherapy reduced the tumor growth.

Downloads

How to Cite

Mathematical Modeling of Strategic Treatments on Tumor Growth. (2014). Global Journal of Science Frontier Research, 14(18), 91-99. https://journalofscience.org/index.php/GJSFR/article/view/

Download Citation

References

Kendall Smith (1988) Interleukin-2: Inception, Impact, and Implications. 240(4856), 1169-1176. https://doi.org/10.1126/science.3131876

R. Repmann, S. Wagner, A. Richter (1997) The use of interleukin 2 in the treatment of renal cell cancer and melanoma proved that an immunological treatment is capable, in some cases, of inducing long term regression of metastatic tumours. 17, 2879-2882.

Cancer chemotherapy, Medline Plus.

R. Martin, M. Fisher, R. Minchin, K. Teo (1990) A mathematical model of cancer therapy with an optimal selection of parameters. 99(2), 205-30.

P. Calabresi, P. Schein (1993) Basic Principles and Clinical Management of Cancer.

J. Holland, Emil Frei, I. (1973) Cancer Medicine.

F. Levi (2002) From circadian rhythms to cancer chronotherapeutics. 19(1), 1-19. https://doi.org/10.1081/cbi-120002676

K. Visser, W. Kast (1999) Effects of TGF-β on the immune system: Implications for cancer immunotherapy. Leukaemia. 13(8), 1188-1199. https://doi.org/10.1038/sj.leu.2401477

A. Cerwenka (1999) TGF-β1: immunosuppressant and viability factor for T lymphocytes. 1, 1291-1296.

Denise Kirschner, John Panetta (1998) Modeling immunotherapy of the tumor - immune interaction. 37(3), 235-252. https://doi.org/10.1007/s002850050127

Trachette Jackson (2002) Vascular tumor growth and treatment: Consequences of polyclonality, competition and dynamic vascular support. 44(3), 201-226. https://doi.org/10.1007/s002850100118

S. Gardner (2000) Gardner, S.N., "A mechanistic, predictive model of dose-response curves for cell cycle phase-specific and nonspecific drugs, Cancer Research, Vol. 60, 1417-1425.

O. Isaeva, V. Osipov (2008) Different strategies for cancer treatment: mathematical modelling. 141980.

Chia-Ling Hsieh, Ding-Shinn Chen, Lih-Hwa Hwang (2000) Tumor-Induced Immunosuppression: A Barrier to Immunotherapy of Large Tumors by Cytokine-Secreting Tumor Vaccine. 11(5), 681-692. https://doi.org/10.1089/10430340050015581

(2006) Mixed immunotherapy and chemotherapy of tumors: modeling, applications and biological interpretations. 238(4), 841-862.

V. Kuznetsov, I. Makalkin (1994) Nonlinear dynamics of immunogenic tumors: Parameter estimation and global bifurcation analysis. 56(2), 295-321. https://doi.org/10.1016/s0092-8240(05)80260-5

J. Folkman, M. Hochberg SELF-REGULATION OF GROWTH IN THREE DIMENSIONS.